{
    "nct_id": "NCT03748706",
    "title": "A Phase 2a, Open-label, Multiple Dose, Safety, Pharmacokinetic and Biomarker Study of PTl-125 in Mild-to-moderate Alzheimer's Disease Patients",
    "status": "COMPLETED",
    "last_update_time": "2021-06-12",
    "description_brief": "This is a Phase 2a, multi-center, open-label study of PTI-125 in mild-to-moderate Alzheimer's disease patients.",
    "description_detailed": "This is a Phase 2a, multi-center, open-label study of PTI-125 in mild-to-moderate AD patients, 50-85 years of age. A total of twelve (12) patients will be enrolled into the study. Patients will receive 100 mg b.i.d. of PTI-125. The objectives of this study are to investigate the safety, pharmacokinetics and effect on biomarkers of PTI-125 following 28-day repeat-dose oral administration.",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "groups": [
                {
                    "id": "FG000",
                    "title": "PTI-125",
                    "description": "PTI-125 100 mg oral tablets administered twice daily (BID)\n\nPTI-125, 100 mg tablets: PTI-125, 100 mg tablets taken twice a day for 28 days"
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "13"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "12"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Lost to Follow-up",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "PTI-125",
                    "description": "PTI-125 100 mg oral tablets administered twice daily (BID)\n\nPTI-125, 100 mg tablets: PTI-125, 100 mg tablets taken twice a day for 28 days"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "13"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "FULL_RANGE",
                    "unitOfMeasure": "Years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "67.8",
                                            "lowerLimit": "56",
                                            "upperLimit": "81"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "9"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "4"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Race (NIH/OMB)",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "American Indian or Alaska Native",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Asian",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Native Hawaiian or Other Pacific Islander",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Black or African American",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "3"
                                        }
                                    ]
                                },
                                {
                                    "title": "White",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "10"
                                        }
                                    ]
                                },
                                {
                                    "title": "More than one race",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Unknown or Not Reported",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Region of Enrollment",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "title": "United States",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "13"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Maximum Plasma Concentration (Cmax)",
                    "description": "Blood draws will be done to evaluate levels of PTI-125 in the plasma using non-compartmental methods in WinNonlin.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "ng/mL",
                    "timeFrame": "Study Day 1 and Day 28 at 20, 40, and 60 min and at 1.5, 2, 2.5, 3, 4, 6, 8, 10 and 12 h post-dose",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "PTI-125",
                            "description": "PTI-125 100 mg oral tablets administered twice daily (BID)\n\nPTI-125, 100 mg tablets: PTI-125, 100 mg tablets taken twice a day for 28 days"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "13"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Day 1 Cmax",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1020",
                                            "spread": "442"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Day 28 Cmax",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1100",
                                            "spread": "417"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Time to Maximum Plasma Concentration (Tmax)",
                    "description": "Levels of PTI-125 will be assessed to determine how long it takes to reach the Cmax",
                    "reportingStatus": "POSTED",
                    "paramType": "MEDIAN",
                    "dispersionType": "Full Range",
                    "unitOfMeasure": "hours",
                    "timeFrame": "Study Day 1 and Day 28 at 20, 40, and 60 min and at 1.5, 2, 2.5, 3, 4, 6, 8, 10 and 12 h post-dose",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "PTI-125",
                            "description": "PTI-125 100 mg oral tablets administered twice daily (BID)\n\nPTI-125, 100 mg tablets: PTI-125, 100 mg tablets taken twice a day for 28 days"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "13"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Day 1 Tmax",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2.00",
                                            "lowerLimit": "1.00",
                                            "upperLimit": "3.00"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Day 28 Tmax",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2.06",
                                            "lowerLimit": "1.00",
                                            "upperLimit": "5.93"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Last Quantifiable Plasma Concentration (Clast)",
                    "description": "Levels of PTI-125 will be assessed to determine the last time point where PTI-125 can be detected.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "ng/mL",
                    "timeFrame": "Study Day 1 and Day 28 at 20, 40, and 60 min and at 1.5, 2, 2.5, 3, 4, 6, 8, 10 and 12 h post-dose",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "PTI-125",
                            "description": "PTI-125 100 mg oral tablets administered twice daily (BID)\n\nPTI-125, 100 mg tablets: PTI-125, 100 mg tablets taken twice a day for 28 days"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "13"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Day 1 Clast",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "176",
                                            "spread": "112"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Day 28 Clast",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "238",
                                            "spread": "168"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Time to Last Quantifiable Plasma Concentration (Tlast)",
                    "description": "Levels of PTI-125 will be assessed to determine the elapsed time to where PTI-125 can last be detected in the plasma.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "hours",
                    "timeFrame": "Study Day 1 and Day 28 at 20, 40, and 60 min and at 1.5, 2, 2.5, 3, 4, 6, 8, 10 and 12 h post-dose",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "PTI-125",
                            "description": "PTI-125 100 mg oral tablets administered twice daily (BID)\n\nPTI-125, 100 mg tablets: PTI-125, 100 mg tablets taken twice a day for 28 days"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "13"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Day 1 Tlast",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "12.0",
                                            "spread": "0.0150"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Day 28 Tlast",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "12.0",
                                            "spread": "0.0285"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Area Under the Curve (AUClast)",
                    "description": "AUC for PTI-125 plasma concentration from time zero to the last quantifiable plasma concentration.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "h*ng/mL",
                    "timeFrame": "Study Day 1 and Day 28 at 20, 40, and 60 min and at 1.5, 2, 2.5, 3, 4, 6, 8, 10 and 12 h post-dose",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "PTI-125",
                            "description": "PTI-125 100 mg oral tablets administered twice daily (BID)\n\nPTI-125, 100 mg tablets: PTI-125, 100 mg tablets taken twice a day for 28 days"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "13"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Day 1 AUClast",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "5320",
                                            "spread": "2230"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Day 28 AUClast",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "6700",
                                            "spread": "3240"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Plasma Half-life (T1/2)",
                    "description": "Assessment of the half-life in plasma of PTI-125",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "hours",
                    "timeFrame": "Study Day 1 and Day 28 at 20, 40, and 60 min and at 1.5, 2, 2.5, 3, 4, 6, 8, 10 and 12 h post-dose",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "PTI-125",
                            "description": "PTI-125 100 mg oral tablets administered twice daily (BID)\n\nPTI-125, 100 mg tablets: PTI-125, 100 mg tablets taken twice a day for 28 days"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "13"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Day 1 T1/2",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "4.51",
                                            "spread": "2.43"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Day 28 T1/2",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "4.35",
                                            "spread": "1.39"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "SavaDx (Biomarker)",
                    "description": "Blood samples will be tested for the complementary diagnostic/biomarker for Alzheimer's disease.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "% change from baseline",
                    "timeFrame": "Study Day 1 and Day 28",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "PTI-125",
                            "description": "PTI-125 100 mg oral tablets administered twice daily (BID)\n\nPTI-125, 100 mg tablets: PTI-125, 100 mg tablets taken twice a day for 28 days"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "13"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-39.8",
                                            "spread": "0.19"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "CSF Biomarkers",
                    "description": "A cerebrospinal fluid sample collection will be performed for A\u03b242, tau, YKL40 and other potential CSF biomarkers",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "% change from baseline",
                    "timeFrame": "Change from Baseline to Day 28",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "PTI-125",
                            "description": "PTI-125 100 mg oral tablets administered twice daily (BID)\n\nPTI-125, 100 mg tablets: PTI-125, 100 mg tablets taken twice a day for 28 days"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "13"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Total tau",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-19.8",
                                            "spread": "0.04"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Abeta42",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "4.3",
                                            "spread": "0.05"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "p-tau181",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-34.4",
                                            "spread": "0.05"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Neurogranin",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-32",
                                            "spread": "0.02"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Neurofilament light chain",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-22",
                                            "spread": "0.02"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "YKL-40",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-9",
                                            "spread": "0.01"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "IL-6",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-14",
                                            "spread": "0.01"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "IL-1 beta",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-11",
                                            "spread": "0.01"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "TNF alpha",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-5",
                                            "spread": "0.01"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "5",
            "timeFrame": "Within the 28-day treatment period.",
            "description": "Moderate; mild; severe Serious; not serious Unlikely; likely; possibly related to drug treatment",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "PTI-125",
                    "description": "PTI-125 100 mg oral tablets administered twice daily (BID)\n\nPTI-125, 100 mg tablets: PTI-125, 100 mg tablets taken twice a day for 28 days",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 13,
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 13,
                    "otherNumAffected": 1,
                    "otherNumAtRisk": 13
                }
            ],
            "otherEvents": [
                {
                    "term": "Fall",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA (Unspecified)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "notes": "Moderate severity; rated as unlikely to be related to treatment.",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 13
                        }
                    ]
                },
                {
                    "term": "B12 deficiency",
                    "organSystem": "Metabolism and nutrition disorders",
                    "sourceVocabulary": "MedDRA (Unspecified)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 13
                        }
                    ]
                },
                {
                    "term": "Hypercalcemia",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA (Unspecified)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 13
                        }
                    ]
                },
                {
                    "term": "Renal colic",
                    "organSystem": "Renal and urinary disorders",
                    "sourceVocabulary": "MedDRA (Unspecified)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 13
                        }
                    ]
                },
                {
                    "term": "Dehydration",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA (Unspecified)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 13
                        }
                    ]
                },
                {
                    "term": "Flu",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA (Unspecified)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 13
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictionType": "OTHER",
                "restrictiveAgreement": true,
                "otherDetails": "Top enrolling PIs are included as authors on Cassava publications, but no individual PI has the right to publish alone without Cassava authorization."
            },
            "pointOfContact": {
                "title": "Lindsay Burns, SVP of Neuroscience",
                "organization": "Cassava Sciences",
                "email": "lburns@cassavasciences.com",
                "phone": "512-501-2484"
            }
        }
    },
    "target_category": "disease-targeted small molecule",
    "drug": [
        "PTI-125 (oral small molecule; binds and restores altered filamin A conformation)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The description and title identify PTI-125 as an investigational therapeutic evaluated in mild-to-moderate Alzheimer\u2019s disease. Published and company sources describe PTI-125 as an oral small-molecule that binds an altered conformation of the scaffolding protein filamin A (FLNA) and restores its native shape, thereby blocking A\u03b242 toxic signaling, reducing tau hyperphosphorylation and neuroinflammation \u2014 i.e., it targets disease biology rather than only symptomatic cognition. \ue200cite\ue202turn0search0\ue202turn0search2\ue201",
        "Act (extracted key details): This is a Phase 2a, multi-center, open-label, multiple-dose safety, PK and biomarker study of PTI-125 in mild-to-moderate AD patients (28-day dosing in the published Phase 2a). The drug is described repeatedly as a small molecule with a disease-modifying mechanism (filamin A target) in peer-reviewed and company publications. \ue200cite\ue202turn0search0\ue202turn0search1\ue201",
        "Web search results (sources supporting the above): - Phase 2a publication showing biomarker reductions and describing PTI-125 as an oral small molecule that reverses altered filamin A conformation. \ue200cite\ue202turn0search0\ue201 - Mechanistic preclinical paper describing PTI-125 binding/reversing altered filamin A and downstream effects on \u03b17-nAChR and TLR4 signaling. \ue200cite\ue202turn0search2\ue201 - Cassava Sciences press release / clinical-trial summary reporting the Phase 2a study design and results (safety, PK, biomarker endpoints). \ue200cite\ue202turn0search1\ue201",
        "Reflect: Given PTI-125 is a small molecule that directly targets a disease-related protein and reduces core AD biomarkers (tau, neurodegeneration and neuroinflammation markers) in patients, the correct category is 'disease-targeted small molecule'. There is no indication PTI-125 is a biologic, a purely symptomatic cognitive enhancer, or an agent aimed only at neuropsychiatric symptoms. \ue200cite\ue202turn0search0\ue202turn0search2\ue201"
    ],
    "agent_type": "I) Proteostasis/Proteinopathies",
    "explanation_agent": [
        "Reason: The investigational drug PTI-125 is described as an oral small molecule that preferentially binds an altered (misfolded/conformationally-changed) form of the scaffolding protein filamin A (FLNA) and restores its native conformation, thereby blocking A\u03b242 toxic signaling and reducing downstream tau hyperphosphorylation and neuroinflammation. This direct action on the conformation/state of a disease-associated protein aligns with proteostasis/proteinopathy mechanisms. \ue200cite\ue202turn0search1\ue202turn0search4\ue201",
        "Act (extracted key details & assignment): PTI-125 \u2014 oral small molecule, binds altered filamin A and restores its shape; Phase 2a was an open-label, multiple-dose (28-day) safety, PK and biomarker study in mild-to-moderate AD showing reductions in P-tau, total tau, NfL and neuroinflammatory markers. Because the primary molecular target is a misfolded/altered endogenous protein (FLNA) and the drug restores protein conformation/function, the most specific CADRO classification is I) Proteostasis/Proteinopathies. \ue200cite\ue202turn0search0\ue202turn0search1\ue201",
        "Reflect: This classification was chosen because CADRO asks to map the direct biological target/mechanism. Although PTI-125 produces downstream effects on A\u03b242 signaling, tau phosphorylation and inflammation, its proximal mechanism is restoration of a disease-altered protein's conformation (proteostasis). An alternative interpretation could consider the compound multi-target because of downstream impacts on amyloid signaling, tau and inflammation; however, CADRO guidance favors the most specific direct target category, so I) is the best fit. \ue200cite\ue202turn0search1\ue202turn0search2\ue201",
        "Web search results (supporting sources cited above): - JPAD / Cassava announcement of Phase 2a publication reporting biomarker reductions and Phase 2a study details (open-label, 28 days). \ue200cite\ue202turn0search0\ue201 - PubMed / mechanistic paper describing PTI-125 binding/reversing altered filamin A and reducing \u03b17-nAChR/TLR4-mediated pathology in preclinical models. \ue200cite\ue202turn0search1\ue201 - Cassava Sciences press releases summarizing Phase 2a results and Phase 2b plans. \ue200cite\ue202turn0search2\ue202turn0search4\ue201"
    ]
}